Status:

RECRUITING

RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

Lead Sponsor:

Peking University People's Hospital

Conditions:

Acute Leukemia

Myelodysplastic Syndromes

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This study aimed to evaluate the efficacy of reduced intensity conditioning (RIC) regimen in elderly or high comorbidity burden patients who receive haploidentical hematopoietic stem cell transplantat...

Detailed Description

RIC regimen was given for elderly patients or those with high comorbidity burden who would receive haplo-HSCT. The elderly patients were defined as older than 55 years. The burden of comorbidities in ...

Eligibility Criteria

Inclusion

  • Patients older than 55 years or those with HCT-CI scores of ≥3, without ISD nor URD, receiving haplo-HSCT

Exclusion

  • patients having identical sibling or unrelated donors; patients with active infection; patients having organ failure; patients with poor compliance.

Key Trial Info

Start Date :

February 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2025

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT03412409

Start Date

February 1 2018

End Date

September 1 2025

Last Update

March 26 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking University, Institute of Hematolgoy

Beijing, China